Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study

Table 4

Response correlations. Patients, tumor characteristics and mutations by response for TKI treated cohort.

	CR or PR (𝑁=4)		SD or PD (𝑁=13)
	𝑁	%	𝑁	%	𝑃
Alcohol					.999
No	2	50.0	5	41.7
Yes	2	50.0	7	58.3
RAS					.235
MUT	1	25.0
WT	3	75.0	13	100.0
EGFR					.541
MUT			3	23.1
WT	4	100.0	10	76.9
HER2					.999
MUT			1	7.7
WT	4	100.0	12	92.3
EGFR (IHC)					.516
Negative			4	33.3
Positive	3	100.0	8	66.7
EGFR (FISH)					.999
Negative	3	100.0	8	72.7
Positive			3	27.3